These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
News & Analysis: Aimmune Therapeutics
AIMT earnings call for the period ending March 31, 2019.
These four experimental drugs will reach the market soon, and the companies launching them have little room for error.
Biotech may be a tough industry to invest in, but we've found three companies within that space that are worth looking into.
No funding for the FDA means delays in drug reviews and approvals. And that could translate to bad news for these three biotechs.
The market's about to find out the FDA does a lot more than check lettuce.
These stocks managed to avoid the market's broad sell-off.
Balancing efficacy and safety is hard.
One biotech's phase 3 failure benefits its competitor.
Here's the latest compelling data from Aimmune, Alnylam, and AstraZeneca.